This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.
We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.
Further to the announcement made on 7 October 2019 regarding the signed agreements with a Fortune 200 company and a data infrastructure specialist, Sensyne Health is now pleased to name Cognizant, the American multinational corporation and leading provider of information technology, consulting, and business process services in healthcare, and Agorai, a data infrastructure specialist, as its partners.
The initial Sensyne Health digital health software products that will be exclusively sold in the US under these agreements are GDm-Health (for the management of gestational diabetes), EDGE (for the management of COPD) and Support-HF (for the management of heart failure). GDm-Health will be launched first, which is currently in use by 15 NHS Trusts and has helped over 6,100 patients in the UK managing and controlling gestational diabetes, a common condition that can lead to high blood pressure, premature birth or the need for Caesarean section. No UK patient data will be shared under these agreements.
These products were originally invented and developed in the UK’s NHS in collaboration with the University of Oxford and then licensed to Sensyne Health. The financial returns made by Sensyne Health under these major agreements with Cognizant and Agorai will be shared with the NHS under Sensyne’s unique partnership model.
“Cognizant and Agorai are excellent partners that will enable us to ensure that the full potential of these innovative products, first invented in the UK’s NHS, is realised in the US market. Following the appropriate regulatory approvals, Cognizant will provide these digital health applications to US health care providers and the commercial return made by Sensyne will be shared with the NHS.”
-ENDS-
For more information please contact:
Sensyne Health
+44 (0) 330 058 1845
Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Joint Broker)
+ 44 (0) 20 7418 8900
Dr Christopher Golden
James Steel
Oliver Jackson
Liberum (Joint Broker)
+ 44 (0) 20 3100 2000
Bidhi Bhoma
Euan Brown
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com
About Cognizant
Cognizant (Nasdaq-100: CTSH) is one of the world's leading professional services companies, transforming clients' business, operating and technology models for the digital era. Our unique industry-based, consultative approach helps clients envision, build and run more innovative and efficient businesses. Headquartered in the U.S., Cognizant is ranked 193 on the Fortune 500 and is consistently listed among the most admired companies in the world. Learn how Cognizant helps clients lead with digital at www.cognizant.com or follow us @Cognizant.
About Agorai
Agorai helps companies accelerate commercial returns from AI solutions and data assets. The team continuously curates applied AI solutions, connecting them with companies that can best benefit from them, and helping those companies to quickly deliver meaningful, bottom-line value. Learn more at www.agorai.ai
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is an early signatory to the U.K Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
Further to the announcement made on 7 October 2019 regarding the signed agreements with a Fortune 200 company and a data infrastructure specialist, Sensyne Health is now pleased to name Cognizant, the American multinational corporation and leading provider of information technology, consulting, and business process services in healthcare, and Agorai, a data infrastructure specialist, as its partners.
The initial Sensyne Health digital health software products that will be exclusively sold in the US under these agreements are GDm-Health (for the management of gestational diabetes), EDGE (for the management of COPD) and Support-HF (for the management of heart failure). GDm-Health will be launched first, which is currently in use by 15 NHS Trusts and has helped over 6,100 patients in the UK managing and controlling gestational diabetes, a common condition that can lead to high blood pressure, premature birth or the need for Caesarean section. No UK patient data will be shared under these agreements.
These products were originally invented and developed in the UK’s NHS in collaboration with the University of Oxford and then licensed to Sensyne Health. The financial returns made by Sensyne Health under these major agreements with Cognizant and Agorai will be shared with the NHS under Sensyne’s unique partnership model.
“Cognizant and Agorai are excellent partners that will enable us to ensure that the full potential of these innovative products, first invented in the UK’s NHS, is realised in the US market. Following the appropriate regulatory approvals, Cognizant will provide these digital health applications to US health care providers and the commercial return made by Sensyne will be shared with the NHS.”
-ENDS-
For more information please contact:
Sensyne Health
+44 (0) 330 058 1845
Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Joint Broker)
+ 44 (0) 20 7418 8900
Dr Christopher Golden
James Steel
Oliver Jackson
Liberum (Joint Broker)
+ 44 (0) 20 3100 2000
Bidhi Bhoma
Euan Brown
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com
About Cognizant
Cognizant (Nasdaq-100: CTSH) is one of the world's leading professional services companies, transforming clients' business, operating and technology models for the digital era. Our unique industry-based, consultative approach helps clients envision, build and run more innovative and efficient businesses. Headquartered in the U.S., Cognizant is ranked 193 on the Fortune 500 and is consistently listed among the most admired companies in the world. Learn how Cognizant helps clients lead with digital at www.cognizant.com or follow us @Cognizant.
About Agorai
Agorai helps companies accelerate commercial returns from AI solutions and data assets. The team continuously curates applied AI solutions, connecting them with companies that can best benefit from them, and helping those companies to quickly deliver meaningful, bottom-line value. Learn more at www.agorai.ai
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is an early signatory to the U.K Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
Further to the announcement made on 7 October 2019 regarding the signed agreements with a Fortune 200 company and a data infrastructure specialist, Sensyne Health is now pleased to name Cognizant, the American multinational corporation and leading provider of information technology, consulting, and business process services in healthcare, and Agorai, a data infrastructure specialist, as its partners.
The initial Sensyne Health digital health software products that will be exclusively sold in the US under these agreements are GDm-Health (for the management of gestational diabetes), EDGE (for the management of COPD) and Support-HF (for the management of heart failure). GDm-Health will be launched first, which is currently in use by 15 NHS Trusts and has helped over 6,100 patients in the UK managing and controlling gestational diabetes, a common condition that can lead to high blood pressure, premature birth or the need for Caesarean section. No UK patient data will be shared under these agreements.
These products were originally invented and developed in the UK’s NHS in collaboration with the University of Oxford and then licensed to Sensyne Health. The financial returns made by Sensyne Health under these major agreements with Cognizant and Agorai will be shared with the NHS under Sensyne’s unique partnership model.
“Cognizant and Agorai are excellent partners that will enable us to ensure that the full potential of these innovative products, first invented in the UK’s NHS, is realised in the US market. Following the appropriate regulatory approvals, Cognizant will provide these digital health applications to US health care providers and the commercial return made by Sensyne will be shared with the NHS.”
-ENDS-
For more information please contact:
Sensyne Health
+44 (0) 330 058 1845
Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Joint Broker)
+ 44 (0) 20 7418 8900
Dr Christopher Golden
James Steel
Oliver Jackson
Liberum (Joint Broker)
+ 44 (0) 20 3100 2000
Bidhi Bhoma
Euan Brown
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com
About Cognizant
Cognizant (Nasdaq-100: CTSH) is one of the world's leading professional services companies, transforming clients' business, operating and technology models for the digital era. Our unique industry-based, consultative approach helps clients envision, build and run more innovative and efficient businesses. Headquartered in the U.S., Cognizant is ranked 193 on the Fortune 500 and is consistently listed among the most admired companies in the world. Learn how Cognizant helps clients lead with digital at www.cognizant.com or follow us @Cognizant.
About Agorai
Agorai helps companies accelerate commercial returns from AI solutions and data assets. The team continuously curates applied AI solutions, connecting them with companies that can best benefit from them, and helping those companies to quickly deliver meaningful, bottom-line value. Learn more at www.agorai.ai
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is an early signatory to the U.K Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
Further to the announcement made on 7 October 2019 regarding the signed agreements with a Fortune 200 company and a data infrastructure specialist, Sensyne Health is now pleased to name Cognizant, the American multinational corporation and leading provider of information technology, consulting, and business process services in healthcare, and Agorai, a data infrastructure specialist, as its partners.
The initial Sensyne Health digital health software products that will be exclusively sold in the US under these agreements are GDm-Health (for the management of gestational diabetes), EDGE (for the management of COPD) and Support-HF (for the management of heart failure). GDm-Health will be launched first, which is currently in use by 15 NHS Trusts and has helped over 6,100 patients in the UK managing and controlling gestational diabetes, a common condition that can lead to high blood pressure, premature birth or the need for Caesarean section. No UK patient data will be shared under these agreements.
These products were originally invented and developed in the UK’s NHS in collaboration with the University of Oxford and then licensed to Sensyne Health. The financial returns made by Sensyne Health under these major agreements with Cognizant and Agorai will be shared with the NHS under Sensyne’s unique partnership model.
“Cognizant and Agorai are excellent partners that will enable us to ensure that the full potential of these innovative products, first invented in the UK’s NHS, is realised in the US market. Following the appropriate regulatory approvals, Cognizant will provide these digital health applications to US health care providers and the commercial return made by Sensyne will be shared with the NHS.”
-ENDS-
For more information please contact:
Sensyne Health
+44 (0) 330 058 1845
Lord (Paul) Drayson, Chief Executive Officer
Lorimer Headley, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Joint Broker)
+ 44 (0) 20 7418 8900
Dr Christopher Golden
James Steel
Oliver Jackson
Liberum (Joint Broker)
+ 44 (0) 20 3100 2000
Bidhi Bhoma
Euan Brown
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott
Sukaina Virji
Melissa Gardiner
sensynehealth@consilium-comms.com
About Cognizant
Cognizant (Nasdaq-100: CTSH) is one of the world's leading professional services companies, transforming clients' business, operating and technology models for the digital era. Our unique industry-based, consultative approach helps clients envision, build and run more innovative and efficient businesses. Headquartered in the U.S., Cognizant is ranked 193 on the Fortune 500 and is consistently listed among the most admired companies in the world. Learn how Cognizant helps clients lead with digital at www.cognizant.com or follow us @Cognizant.
About Agorai
Agorai helps companies accelerate commercial returns from AI solutions and data assets. The team continuously curates applied AI solutions, connecting them with companies that can best benefit from them, and helping those companies to quickly deliver meaningful, bottom-line value. Learn more at www.agorai.ai
About Sensyne Health
Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is an early signatory to the U.K Department of Health and Social Care’s ‘Initial Code of Conduct for data-driven health and care technology. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
